Tandem CAR-T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time
This is the first time using a tandem CAR design targeting meso and MUC16, and demonstrating a benefit on tumor control over monospecific CAR-T cells. Tandem CAR-T cells targeting meso and MUC16ecto could be employed as a strategy to overcome tumor cell heterogeneity in ovarian and pancreatic tumors, and may help to design therapeutic approaches relying on its one-antigen-at-a-time binding properties and on its antigen-driven killing of tumor cells based on antigen density.
Authors
- J. Frank (ORCID: https://orcid.org/0000-0001-5334-3240)
- S Goncalves (ORCID: https://orcid.org/0000-0001-8713-2249)
- Mark B. Leick (ORCID: https://orcid.org/0000-0003-3111-0221)
- Marcela V. Maus (ORCID: https://orcid.org/0000-0002-7578-0393)
- Trisha R. Berger (ORCID: https://orcid.org/0000-0003-3439-3239)
- Diego Salas‐Benito (ORCID: https://orcid.org/0000-0002-8995-1499)
- Tamina Kienka
- Filippo Birocchi (ORCID: https://orcid.org/0000-0002-5214-233X)
- Aiyana Parker (ORCID: https://orcid.org/0009-0001-9037-641X)
- Amanda A. Bouffard (ORCID: https://orcid.org/0009-0003-1501-4384)
- Giulia Escobar (ORCID: https://orcid.org/0000-0001-9177-0251)
- Bo R. Rueda (ORCID: https://orcid.org/0000-0001-9489-8699)
- Eugene Kim (ORCID: https://orcid.org/0000-0002-4815-5680)
- Sangwoo Park (ORCID: https://orcid.org/0000-0002-2701-3114)
- Alexander Armstrong (ORCID: https://orcid.org/0009-0003-6957-9903)
- Kiana Graham
- Christine Ho (ORCID: https://orcid.org/0009-0007-7122-5310)
- Christopher Kelly (ORCID: https://orcid.org/0009-0006-6220-4588)
Institutions
- Harvard University (US)
- Massachusetts General Hospital (US)
- Reproductive Science Center (US)
- Center for Cancer Research (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1136/jitc-2025-012822
- Citations
- 6
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 6.27